Glibenclamide administered by the intravenous route as a therapeutic intervention for ischemic stroke has been undergoing testing in clinical trials due to its suppression of sulfonylurea receptor-1-transient receptor potential melastatin-4(SUR1-TRPM4) ion channels which mitigates oedema and hemorrhagic transformation [50]. This evidence concerns the gene ABCC8 and ischemic stroke.